Immune system versus metastatic cancer cells
One of the hallmarks of cancer is metastasis: the ability of cancer cells to escape the primary tumour, migrate and colonise distant sites. Significant evidence over the years has highlighted the process, yet little is known about how these cells escape immune recognition. The EU-funded EVOMET project is focusing on colorectal cancer, which has a very low survival rate once metastatic. Researchers are working under the hypothesis that metastatic cancer cells escape immune surveillance through the suppression of neoantigens. Being able to quantify the relation between the immune system and tumour cells will pave the way for novel anti-cancer interventions.